AHZ FY18, page-9

I think ralom has a fair point.
There was always some blue sky factored into this companies share price.

Whether it was blue sky around the vax or the potential sales of cardiocel.
This blue sky has been well and truly removed from the share price.
The reality is they have a good product in a tough market, have broken in and are going in the right direction

another quote from Wayne's first Webinar.
"CardioCel, a pipeline in a product, so why is uptake slower than the investors expected ?
• We did not communicate expectations well"

The reality is its a slow grind for cardiocel and manufacturing needed refinement, and while the vax isnt dead it is apparent that it isnt the silver bullet as is, that everyone hoped for.

FY18 could be a good solid year.
I hope to see continued focus on expenditure control
Keeping manufacturing performance up
Increased sales
and of course increased share price.

Lets see the final numbers for this year, but i think they will good enough to indicate they can deliver a good FY 18 if they continue on this path.